11/19/2026 | Press release | Distributed by Public on 11/19/2026 13:09
NEWPORT BEACH, Calif., November 19, 2026 - CureDuchenne, a leading global nonprofit dedicated to finding a cure and improving care for individuals with Duchenne (DMD) and Becker muscular dystrophy (BMD), announced a funding commitment to establish the CureDuchenne Adult Multidisciplinary Program at Penn Medicine. Dedicated exclusively to adults living with DMD or BMD, the program will bring together medical specialists and dedicated clinical staff to address the complex and growing healthcare needs of this population.
Advances in research and medical care are helping people with Duchenne muscular dystrophy live longer, creating an urgent need for adult healthcare services specialized in the increased, complex needs of the adult Duchenne patient. Approximately 15,000 individuals in the United States are living with DMD, and a growing number are reaching adulthood. A 2021 study published in Neurology found that median life expectancy increased from 18.3 years for individuals born before 1970 to 28.1 years for those born after 1990. Yet adult healthcare services have not kept pace with this progress, leaving many adults navigating complex medical needs across fragmented healthcare systems.
"We've made tremendous progress in Duchenne research, helping more people live longer lives. Now we need to make sure the care available to them keeps pace," said Debra Miller, founder and CEO of CureDuchenne. "Adults with Duchenne or Becker deserve the highest standards of specialized care, with experts who understand their needs and work together to provide comprehensive support. We're proud to partner with Penn Medicine providers to strengthen these services for adults and families throughout the Mid-Atlantic region."
Led by Lauren Elman, M.D., Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania, the program will build on Penn Medicine's established adult neuromuscular expertise to provide more comprehensive, coordinated care. CureDuchenne's funding commitment will support dedicated clinical staff, including a nurse navigator, dietitian and physical therapist, as well as clinical leadership and coordination across medical specialties. Located at the Penn Neuroscience Center within the Perelman Center for Advanced Medicine, the program will bring together specialists in neurology, cardiology, pulmonology, rehabilitation, nutrition and other areas to address the complex healthcare needs of adults with Duchenne or Becker muscular dystrophy. A central focus will be helping patients and families navigate appointments, specialists, and ongoing care.
Penn Medicine currently cares for more than 110 adult patients with Duchenne or Becker muscular dystrophy, representing one of the largest adult neuromuscular populations in the country. Philadelphia is uniquely positioned for this program because of the longstanding collaboration between Penn Medicine and Children's Hospital of Philadelphia (CHOP), which supports patients as they transition from pediatric to adult healthcare services. As advances in care continue to extend life expectancy, the number of adults living with Duchenne is expected to grow, increasing the need for specialized adult-focused programs.
"Adults living with Duchenne face medical challenges that are often very different from those experienced in childhood," said Brenda Wong, M.D., CureDuchenne Chief Medical Advisor and an internationally recognized Duchenne specialist. "As the disease progresses, individuals need careful management of heart and respiratory health, nutrition, mobility and other complications. These needs cannot be addressed in isolation. A coordinated team of specialists who understand Duchenne is essential to helping adults maintain their health, independence and quality of life."
"We are seeing more young men with Duchenne graduate from pediatric care into the adult world and live for decades with complex medical needs," said Lauren Elman, M.D. "Our multidisciplinary team at Penn is comprised of experts in their respective fields who have extensive experience caring for individuals with neuromuscular disease. Now, with CureDuchenne's support, we can enhance the transition from pediatric care at CHOP, strengthen coordination of care for patients, and provide additional clinical resources to better meet the needs of our patients as they grow older."
For more information about the CureDuchenne Adult Multidisciplinary Program at Penn Medicine or to support the program, visitwww.cureduchenne.org/care/clinic/.
About CureDuchenne
Over 20 years ago, CureDuchenne was created with one goal: to find and fund a cure for Duchenne muscular dystrophy, one of the most common and severe forms of muscular dystrophy. Today, CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne. CureDuchenne's innovative venture philanthropy model has advanced transformative treatments for Duchenne muscular dystrophy, including 20 projects that advanced to human clinical trials and multiple projects to overcome the limitations of exon-skipping and gene therapy. In addition, CureDuchenne contributed early funding to the first FDA-approved Duchenne drugs and pioneered the first and only Duchenne physical and occupational therapist certification program. For more information on how to help raise awareness and funds needed for research, please visit cureduchenne.org or follow us on Facebook, Instagram, LinkedIn, and X.
###